User profiles for "author:GIOVANNI B FRISONI"

Giovanni B Frisoni

Director, Centre de la mémoire
Verified email at unige.ch
Cited by 78541

Alzheimer's disease

P Scheltens, K Blennow, MMB Breteler, B De Strooper… - The Lancet, 2016 - thelancet.com
Although the prevalence of dementia continues to increase worldwide, incidence in the
western world might have decreased as a result of better vascular care and improved brain …

Defeating Alzheimer's disease and other dementias: a priority for European science and society

B Winblad, P Amouyel, S Andrieu, C Ballard… - The Lancet …, 2016 - thelancet.com
Executive summary Alzheimer's disease (AD) is the leading cause of dementia, and
because the primary risk factor for AD is old age, the prevalence of the disease is increasing …

Preclinical Alzheimer's disease: definition, natural history, and diagnostic criteria

B Dubois, H Hampel, HH Feldman, P Scheltens… - Alzheimer's & …, 2016 - Elsevier
During the past decade, a conceptual shift occurred in the field of Alzheimer's disease (AD)
considering the disease as a continuum. Thanks to evolving biomarker research and …

Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria

B Dubois, HH Feldman, C Jacova, H Hampel… - The Lancet …, 2014 - thelancet.com
In the past 8 years, both the International Working Group (IWG) and the US National Institute
on Aging–Alzheimer's Association have contributed criteria for the diagnosis of Alzheimer's …

Distinct patterns of brain activity in young carriers of the APOE-ε4 allele

N Filippini, BJ MacIntosh, MG Hough… - Proceedings of the …, 2009 - National Acad Sciences
The APOE ε4 allele is a risk factor for late-life pathological changes that is also associated
with anatomical and functional brain changes in middle-aged and elderly healthy subjects …

Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis

WJ Jansen, R Ossenkoppele, DL Knol, BM Tijms… - Jama, 2015 - jamanetwork.com
Importance Cerebral amyloid-β aggregation is an early pathological event in Alzheimer
disease (AD), starting decades before dementia onset. Estimates of the prevalence of …

The clinical use of structural MRI in Alzheimer disease

GB Frisoni, NC Fox, CR Jack Jr, P Scheltens… - Nature Reviews …, 2010 - nature.com
Structural imaging based on magnetic resonance is an integral part of the clinical
assessment of patients with suspected Alzheimer dementia. Prospective data on the natural …

A/T/N: an unbiased descriptive classification scheme for Alzheimer disease biomarkers

CR Jack Jr, DA Bennett, K Blennow, MC Carrillo… - Neurology, 2016 - AAN Enterprises
Biomarkers have become an essential component of Alzheimer disease (AD) research and
because of the pervasiveness of AD pathology in the elderly, the same biomarkers are used …

Clinical diagnosis of Alzheimer's disease: recommendations of the International Working Group

B Dubois, N Villain, GB Frisoni, GD Rabinovici… - The Lancet …, 2021 - thelancet.com
Summary In 2018, the US National Institute on Aging and the Alzheimer's Association
proposed a purely biological definition of Alzheimer's disease that relies on biomarkers …

The probabilistic model of Alzheimer disease: the amyloid hypothesis revised

GB Frisoni, D Altomare, DR Thal, F Ribaldi… - Nature Reviews …, 2022 - nature.com
The current conceptualization of Alzheimer disease (AD) is driven by the amyloid
hypothesis, in which a deterministic chain of events leads from amyloid deposition and then …